BBI News and Press, Brickell Biotech Inc. From 11/22/20

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Are These Biotech Penny Stocks On Your Watch List Today? Have you seen some of the biotech penny stocks today? If not, you might want to take a peek at the sector itself. With news from Pfizer that its final results on a coronavirus vaccine recorded 95% efficacy, traders are on the ...

Brickell Biotech's (BBI) Japanese development partner, Kaken Pharmaceutical plans to launch sofpironium bromide gel, 5% under the brand name ECCLOCK in Japan for the once daily treatment of primary axillary (underarm) hyperhidrosis on November 26, 2020.In addition, ECCLOCK has been place...

Kaken plans to launch ECCLOCK ® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020 - - - ECCLOCK ® placed on Japan’s National Health Insurance (NHI) drug reimbursement price list BOUL...

BOULDER, Colo., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today ann...

Brickell Biotech, Inc. (BBI) Q3 2020 Earnings Conference Call November 12, 2020, 16:30 PM ET Company Participants Dan Ferry - Investor Relations, LifeSci Advisors Robert Brown - Chief Executive Officer Deepak Chadha - Chief R&D Officer Michael Carruthers - Chief Financial Officer Conferen...

BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today ann...

Brickell Biotech (BBI) down 6.4% premarket on pricing public offering of 20,833,322 common shares or common stock equivalents and investor five-year warrants to purchase 20,833,322 common shares at a combined offering price of $0.72/share, for total gross proceeds of ~$15M.Offering ...

BOULDER, Colo., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today ann...